A Multicenter Comparative Study Comparing Different Conditioning Protocols (Namely: Cyclophosphamide, Melephalan, Etoposide versus Bendamustine, Etoposide, Cytarabine, Melphalan) in Autologous Stem Cell Transplantation among Egyptian Patients with Hodgkin Disease

Abstract

ost patients with classical Hodgkin lymphoma (cHL) will be cured with standard frontline therapy, but 20% of patients will be refractory or relapse after cytotoxic chemotherapy, radiation therapy, or a combination of the two. Some of these patients may be cured by salvage chemotherapy and autologous stem cell transplant (autoSCT). However, those who have refractory or relapsed disease after autoSCT have poor prognosis with conventional therapies and a median overall survival (OS) of about 25 months. In recent years, outcomes have been improving in the post-autoSCT relapsed setting as new therapies such as immune checkpoint inhibitors have emerged for relapsed/refractory cHL (R/R cHL).